Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Milei Threatens Falkland Oil Firms With Sanctions 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Anthropic IPO Marketing Expected to Start in Mid-October 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Add as a preferred source on Google
ROSELAND, N.J., Feb. 22, 2018 -- Novo Nordisk announced today the successful completion of the first phase 3a trial, PIONEER 1, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere Technologies, Inc.’s (“Emisphere” or the “Company”) proprietary Eligen® Technology.
A copy of Novo Nordisk’s announcement can be found at https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2170941.html
About Emisphere
Emisphere is a drug delivery company that utilizes its proprietary Eligen® Technology to develop new oral formulations of therapeutic agents. Emisphere is currently partnered with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, please visit the Company's website at www.emisphere.com.
The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development activities and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the Company's business development activities and the sufficiency of the Company's cash position. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including , but not limited to, the sufficiency of Emisphere’s cash position, the success of our and our partner’s development and commercialization efforts, and our ability to successfully partner our Eligen® Technology.
CONTACT: Philip Nikolayuk, Finance Director & IR 973.532.8014 [email protected]
